Carbognin, Luisa
 Distribuzione geografica
Continente #
NA - Nord America 966
EU - Europa 858
AS - Asia 346
OC - Oceania 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.175
Nazione #
US - Stati Uniti d'America 965
GB - Regno Unito 339
CN - Cina 303
SE - Svezia 123
IT - Italia 104
IE - Irlanda 94
FR - Francia 71
DE - Germania 68
FI - Finlandia 27
KR - Corea 19
UA - Ucraina 16
JP - Giappone 5
NL - Olanda 5
RU - Federazione Russa 4
VN - Vietnam 4
IR - Iran 3
TR - Turchia 3
AU - Australia 2
BE - Belgio 2
SG - Singapore 2
TW - Taiwan 2
UZ - Uzbekistan 2
AZ - Azerbaigian 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
EU - Europa 1
IN - India 1
LU - Lussemburgo 1
NO - Norvegia 1
PL - Polonia 1
RO - Romania 1
SA - Arabia Saudita 1
Totale 2.175
Città #
Southend 328
Chandler 263
Woodbridge 133
Dublin 94
Beijing 77
New York 61
Jacksonville 57
Ann Arbor 44
Ashburn 36
Lawrence 31
Princeton 31
Verona 30
Wilmington 28
Jinan 25
Shenyang 25
Nanjing 23
Tianjin 21
Seoul 19
Hebei 13
Houston 12
Zhengzhou 12
Sindelfingen 11
Changsha 10
Guangzhou 9
Ningbo 8
Haikou 6
Hangzhou 6
Seattle 6
Taiyuan 6
Los Angeles 5
Markgröningen 5
Milan 5
Nanchang 5
Redmond 5
Redwood City 5
Augusta 4
Cagliari 4
Dearborn 4
Helsinki 4
Lancaster 4
Rome 4
Taizhou 4
Bologna 3
Clearwater 3
Detroit 3
Frankfurt am Main 3
Fremont 3
Jiaxing 3
Mountain View 3
Riva 3
San Mateo 3
Sant'Ambrogio di Valpolicella 3
Washington 3
Amsterdam 2
Brussels 2
Cambridge 2
Düsseldorf 2
Florence 2
Fuzhou 2
Hamburg 2
Norwalk 2
Pozza 2
Saint Louis 2
San Francisco 2
Singapore 2
Sossano 2
Taipei 2
Tashkent 2
Ardabil 1
Austin 1
Baku 1
Boydton 1
Canberra 1
Castelnuovo 1
Changle 1
Chicago 1
Dallas 1
Fairfield 1
Groningen 1
Istanbul 1
Kashan 1
Kochi 1
Lanzhou 1
London 1
Luxembourg 1
Mainz 1
Mehlingen 1
Melbourne 1
Miami 1
Negrar 1
Newark 1
Padova 1
Pordenone 1
Puxian 1
Riva Del Garda 1
Rohnert Park 1
Rovereto 1
San Diego 1
San Godenzo 1
San José 1
Totale 1.578
Nome #
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 113
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 100
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 100
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 96
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 94
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 94
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 93
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 86
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 85
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 85
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 82
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 80
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 77
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 68
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 68
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 64
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 63
Identification of clinical, pathological and molecular predictors of prognosis in early-stage invasive lobular breast cancer: role of proliferation and CDK4/6 pathway. 63
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 62
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 61
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 60
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 57
Muscle derangement and alteration of the nutritional machinery in NSCLC 56
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 55
The obesity paradox in cancer: clinical insights and perspectives 53
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 53
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 52
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 51
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 44
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 40
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. 36
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 25
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 15
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 5
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 5
Totale 2.241
Categoria #
all - tutte 7.167
article - articoli 6.744
book - libri 0
conference - conferenze 233
curatela - curatele 0
other - altro 190
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.334


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201936 0 0 0 0 0 0 0 0 0 0 10 26
2019/2020267 36 7 1 9 31 25 38 16 32 19 20 33
2020/2021212 27 37 12 45 24 19 2 2 7 5 26 6
2021/2022269 20 92 0 33 11 3 3 8 13 6 15 65
2022/2023645 36 90 39 134 57 151 3 37 64 1 20 13
2023/2024295 14 24 16 27 54 75 7 32 10 34 2 0
Totale 2.241